After much frustration in the last decade, HIV therapeutics is an emerging discipline. Over the past few years a number of new agents have been evaluated, including such antiviral drugs as zidovudine, dideoxycytidine and dideoxyinosine, and immunomodulators such as alpha interferon and interleukin-2. The author discusses these and other agents and the prospects for combination therapy.